Grandbrothers/iStock Editorial via Getty Images Regeneron ( NASDAQ: REGN ) announced Tuesday that the U.S. FDA has expanded the approval for its arthritis therapy Kevzara (sarilumab), developed with Sanofi ( NASDAQ: SNY ), allowing its use in children with the joint disorder active polyarticular juvenile idiopathic arthritis (pJIA).
pJIA is a painful arthritic condition that leads to inflammation in multiple joints. Kevzara's latest approval brings a new FDA-licensed therapy to help address the disorder, Regeneron ( REGN ) CEO George Yancopoulos said. Kevzara is designed to target the IL-6 receptor, a cellular compound synthesized in large quantities in patients with rheumatoid arthritis, leading to joint destruction and other issues.
In the U.S., the injectable was previously approved as a late-line therapy for adults with rheumatoid arthritis and polymyalgia rheumatica.
"This milestone highlights our ongoing commitment to bringing medicines to our younger patients living with this chronic condition that can cause debilitating joint pain and inflammation," Sanofi's ( SNY ) Specialty Care head Brian Foard added. More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals, Inc.
(REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks GSK, Pfizer to appeal Delaware ruling that allow.
